Elvina Almuradova: Our Recent Meta-analysis on the Impact of Omitting The 5-FU Bolus From Chemotherapy Regimens
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“In our recent meta-analysis including 7 studies and 12,698 patients with metastatic gastrointestinal cancers, we evaluated the impact of omitting the 5-FU bolus from chemotherapy regimens.
Key Findings:
- No significant difference in PFS (HR: 0.94) or OS (HR: 0.96) between 5-FU bolus vs infusion-only groups.
- However, the 5-FU bolus group had significantly higher rates of:
- Grade 3–4 neutropenia (OR: 0.46)
- Any-grade thrombocytopenia (OR: 0.53)
- No significant differences in febrile neutropenia, diarrhea, or nausea.
Conclusion: Omitting the bolus form of 5-FU may reduce hematologic toxicity without compromising survival — a meaningful step toward safer chemotherapy protocols in GI cancers.
We hope this contributes to evolving treatment standards and informed decision-making in clinical oncology.”
Title: Efficacy and safety of omitting 5-fluorouracil bolus in combination chemotherapy regimens for gastrointestinal cancers: a systematic review and meta-analysis
Authors: Yusuf Ilhan, Onur Yazdan Balcık, Elif Sahın, Aysegul Merc Cetınkaya, Elvina Almuradova, Murat Bardakcı, Cigdem Dınckal, Murat Karateke, Kadriye Bır Yucel, Arif Hakan Onder, Yakup Ergun
You can read the Full Article on Expert Opinion on Drug Safety
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023